InSite Vision to Report Fourth Quarter and Year-End 2012 Financial Results on March 5, 2013
InSite Vision to Report Fourth Quarter and Year-End 2012 Financial Results on March 5, 2013
ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the fourth quarter and year ended December 31, 2012 on Tuesday, March 5, 2013.
Company management will host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to discuss fourth quarter and full year 2012 financial results and to review recent accomplishments and upcoming milestones. Investors will be invited to ask questions following management's prepared remarks.
Analysts and investors can participate in the conference call by dialing 888-680-0893 for domestic callers and 617-213-4859 for international callers using the pass code 55013640. A telephone replay will be available following the conclusion of the call by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers using the pass code 60004268.
The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. A press release detailing fourth quarter and full year 2012 financial results will be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.
About InSite Vision
InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.
The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus™ and DexaSite™ for the treatment of eye infections, and BromSite™ for pain and inflammation associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com.
AzaSite®, DuraSite® and DuraSite 2® are registered trademarks of InSite Vision Incorporated.
AzaSite Plus™, BromSite™ and DexaSite™ are trademarks of InSite Vision Incorporated.
BESIVANCE® is a registered trademark of Bausch + Lomb Incorporated.
InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
mail@insite.com
or
Media and Investor Inquiries
BCC Partners
Michelle Corral, 415-794-8662
Karen L. Bergman, 650-575-1509
KEYWORDS: United States North America California
INDUSTRY KEYWORDS:
The article InSite Vision to Report Fourth Quarter and Year-End 2012 Financial Results on March 5, 2013 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
